

[First Hit](#) [Fwd Refs](#)[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)[End of Result Set](#) [Generate Collection](#) | [Print](#)

L11: Entry 1 of 2

File: USPT

Nov 6, 2001

US-PAT-NO: 6312691

DOCUMENT-IDENTIFIER: US 6312691 B1

**** See image for Certificate of Correction ****

TITLE: Lymphotoxin-.alpha./.beta. complexes and anti-lymphotoxin-.beta. receptor antibodies as anti-tumor agents

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Browning; Jeffrey L.	Brookline	MA	02146	
Meier; Werner	Burlington	MA	01803	
Benjamin; Christopher D.	Beverly	MA	01915	

US-CL-CURRENT: 424/143.1; 424/130.1, 424/144.1, 424/809, 530/388.22, 530/388.7,
530/388.75, 530/388.8, 530/388.85

CLAIMS:

What is claimed is:

1. A method for treating or reducing the advancement, severity or effects of neoplasia comprising the step of administering a therapeutically effective amount of at least one LT-.beta.-R activating agent and a pharmaceutically acceptable carrier wherein at least one LT-.beta.-R activating agent comprises an anti-LT-.beta.-R antibody.
2. The method according to claim 1, wherein the anti-LT-.beta.-R antibody is CBE11 (ATCC Accession No. 11793).
3. A pharmaceutical composition comprising a therapeutically effective amount of at least one anti-LT-.beta.-R activating agent wherein one anti-LT-.beta.-R activating agent is an anti-LT-.beta.-R antibody.
4. The pharmaceutical composition according to claim 3, wherein the anti-LT-.beta.-R antibody is a monoclonal antibody.
5. The pharmaceutical composition according to claim 4, wherein the anti-LT-.beta.-R monoclonal antibody is selected from the group consisting of anti-LT-.beta.-R mAb CBE11 (ATCC Accession No. 11793), BKA11 (ATCC Accession No. 11799), CDH10 (ATCC Accession No. 11797), BCG6 (ATCC Accession No. 11794), and BHA10 (ATCC Accession No. 11795).

[Previous Doc](#) [Next Doc](#) [Go to Doc#](#)



National
Library
of Medicine

Entrez PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

B

Search for [About Entrez](#)

- Search History will be lost after eight hours of inactivity.

[Text Version](#)

- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

Search	Most Recent Queries	Time	Result
	#11 Search LYMPHOTOXIN beta receptor	11:23:52	160
	#9 Search lymphotoxin beta receptor antibody	11:09:58	46
	#8 Search anti-lymphotoxin beta receptor	11:09:43	0
	#7 Search anti-lymphotoxin beta receptor antibodies	11:09:38	0
	#6 Related Articles for PubMed (Select 8171323)	10:43:19	127
	#4 Search lymphotoxin beta receptor	10:40:02	160
	#2 Related Articles for PubMed (Select 8642291)	10:38:28	104
	#1 Search lymphotoxin beta receptor AND antibod*	10:35:32	34

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement | Freedom of Information Act | Disclaimer](#)

```
=> s lymphotoxin (5a) beta (p) antibod?
L1      1123 LYMPHOTOXIN (5A) BETA (P) ANTIBOD?

=> s (lymphotoxin (5a) beta (5a) receptor) (p) antibod?
L2      203 (LYMPHOTOXIN (5A) BETA (5A) RECEPTOR) (P) ANTIBOD?

=> dup rem 12
PROCESSING COMPLETED FOR L2
L3      136 DUP REM L2 (67 DUPLICATES REMOVED)

=> s l3 and (cancer or neopl?)
L4      83 L3 AND (CANCER OR NEOPL?)

=> dup rem 14
PROCESSING COMPLETED FOR L4
L5      83 DUP REM L4 (0 DUPLICATES REMOVED)

=> s l5 not py=>1996
'1996' NOT A VALID FIELD CODE
  6 FILES SEARCHED...
L6      0 L5 NOT PY=>1996

=> s l5 not py=>1997
'1997' NOT A VALID FIELD CODE
  6 FILES SEARCHED...
L7      1 L5 NOT PY=>1997
```